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Abstract 
Despite the high prevalence and devastating outcome of ischemic stroke, 
there remain few options for treatment following stroke onset. The treatments 
that are currently available remain limited both in the time window following 
stroke in which they are effective, as well as their success in ameliorating stroke 
injury in the brain and limiting functional impairment. Current therapies for stroke, 
such as tissue plasminogen activator (tPA) are only effective up to 4.5 hours 
following stroke onset. We have tested a human umbilical cord blood-derived 
stem cell line that has shown both a significant reduction in stroke infarct volume 
as well as improved functional recovery following stroke in the rat when 
administered 48 hours following stroke onset. In the present study we have 
compared high vs. low passage non-hematopoietic umbilical cord blood stem 
cells (nh-UCBSCs) to determine whether highly expanded nh-UCBSCs are as 
therapeutically effective as low passaged cells, and their mechanisms of action. 
Using the middle cerebral arterial occlusion (MCAO) model of stroke in Sprague-
Dawley rats, we administered nh-UCBSC by intra-venous administration two 
days following stroke induction. These human cells were injected into rats without 
any immune suppression, and no adverse reactions were detected.  Both 
behavioral and histological analyses have shown that the administration of these 
cells reduces the infarct volume by 50% as well as improve the functional 
outcome of these rats following stroke for both high and low passaged nh-
UCBSC. The brain transcriptome was compared between normal rats, and those 
with ischemic brain injury, and injury with nh-UCBSC treatment using next 
generation RNAseq analysis. Differences in the brain transcriptome revealed that 
ischemic brain injury was associated with significant increases in transcripts 
related to macrophage, T cell, and microglia function.  Flow cytometry analysis of 
immune cells present in the brains of animals, in each of these three groups, 
confirmed infiltration of macrophages and T cells consequent to ischemia 
reduction to normal levels with nh-UCBSC treatment.  Flow cytometry also 
revealed a restoration of normal levels of microglia in the brain following 
treatment. Overall, these data show a blunting of immune cell migration and 
activation that are typically activated in the brain following stroke, suggesting that 
nh-UCBSCs may act by inhibiting immune cell migration into the brain from the 
periphery, and possibly by inhibition of immune cell activation within the brain. 
Non-hematopoietic umbilical cord blood stem cells exhibit great potential to 
provide a novel therapy for stroke with no known ill-effects, and are effective at 
later time points following stroke than methods that are currently available in the 
clinic.  
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ABSTRACT  
Stem cells have been touted as a potential source of cells for repair in 
regenerative medicine.  When transplanted into the central nervous system 
stem cells have been shown to differentiate in to neurons and glia.  Recent 
studies, however, have also revealed neuroprotective properties of stem 
cells. These studies suggest that various types of stem cells are able to 
protect against the loss of neurons in conditions of ischemic brain injury.  In 
this article we discuss the use of stem cells for ischemic stroke and the 
parameters under which neuroprotection can occur in the translation of 
stem cell therapy to the clinical setting. 
 
INTRODUCTION 
Stroke is one of the most common causes of death in the United States, with 
over 750,000 cases per year in the US (Roger et al. 2012). Moreover, those who 
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suffer stroke and survive do so at great cost to society, with direct costs 
estimated at $18.8 billion per year (Roger et al. 2012). Despite the high 
prevalence of stroke, there remain only limited options for therapy in the clinic, 
none of which are effective for restoring lost neurological function. In addition, 
available treatments are only effective at the acute phase of stroke. The lack of 
effective treatments for such a pervasive disease have made novel approaches 
to stroke therapy a focus of both preclinical and clinical research in recent years. 
One of the most prominent approaches to stroke therapy that is emerging from 
this body of research is the use of exogenous stem cells as a therapy for 
ameliorating stroke deficits and restoring neurological function. 
 
TREATMENT 
Currently available treatments for ischemic stroke focus on revascularization – 
removal of the clot in the brain to restore normal blood flow, while restoring 
normal cranial pressure to reduce damage due to swelling. The only currently 
proven therapy for stroke is tissue plasminogen activator (tPA) which disrupts the 
clot, but is only effective if administered via IV within 4.5 hours of the stroke 
occurrence, or delivered via IA administration up to 6 hours following stroke 
(Donnan et al. 2003).  
In addition, there are surgical methods of mechanically removing the clot, but 
these methods are very invasive and carry their own risks. Devices have been 
developed to mechanically disrupt the clot, such as the penumbra system, which 
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operates by aspirating and extracting the thrombus (Bose et al. 2008), and the 
Merci Clot Retrieval Device, which also mechanically removes the embolism and 
restores blood flow (Kim et al. 2006). The Solitaire Revascularization Device is a 
stent-based device that allows immediate restoration of blood flow with the 
placement of a stent, followed by clot removal (Jahan 2010). These surgical 
interventional techniques have shown benefit, but there are no double-blinded, 
randomized, controlled studies showing this benefit, and any studies conducted 
have only involved small patient numbers. While the methods for restoring blood 
flow to areas of ischemia are improving, we have yet to improve stroke outcome 
over what was first demonstrated in the NINDS trial in 1995 with IV tPA at <3 
hours after stroke onset (Group 1995). 
The most critical factor affecting stroke therapy is that currently only 5% of 
patients are treated for stroke (Roger et al. 2012). There are many factors which 
contribute to this fact, including a lack of public awareness of stroke symptoms, 
and lack of ability to reach appropriate care in time for current treatments to be 
effective. Due to these facts, there is a great need to develop additional therapies 
for patients at later time points, and for those who have a completed infarct. Stem 
cell based therapies are proving to be very promising candidates for treatments 
that are not only effective at later time points following stroke onset, but 
addressing the complex pathophysiology of stroke and providing neurological 
repair. This review will outline current preclinical and clinical research in the 
emerging field of stem cell therapeutics in stroke research.  
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STEM CELL THERAPIES 
Historically, the dogma put forth by Ramon Y Cajal that the total number of 
cells in the brain were fixed and that there was no cellular regeneration or 
presence of endogenous stem cells in the brain was widely accepted (Colucci-
D'Amato, Bonavita and di Porzio 2006). This dogma was accepted well into the 
20th century, until studies by Altman and Das (1965) provided evidence for the 
existence of stem cells in the brain.  These early studies on neural stem cells as 
the basis for neurogenesis were subsequently confirmed by the Nottebohm 
group (Nottebohm 1989). The discovery of neurogenesis in the brain lead to the 
discovery of neurogenic niches in the subventricular zone (SVZ) and the dentate 
gyrus (DG) (Doetsch 2003). Research in the field also revealed enhanced 
neurogenesis after injury in both neurogenic niches as well as non-neurogenic 
regions such as the cortex and striatum (Parent 2003). These discoveries have 
opened the door for investigating the potential use of endogenous neurogenesis 
as a treatment of stroke.  
A. Neuroregeneration 
One of the potential mechanisms by which stem cells can provide therapy for 
stroke victims is through neuroregeneration. In order for stem cells to produce 
successful neuroregeneration, several conditions must be met: they must be able 
to produce multiple types of neurons and glia; the new cells must be able to 
migrate to the site of injury; and they must be able to integrate with existing 
circuitry by initializing and maintaining appropriate functional connections with 
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neighboring cells. The adult brain is populated by endogenous stem cells known 
as neural stem cells (NSCs) which are capable of differentiating into different 
types of neurons and glia (Weiss et al. 1996). 
Many in vivo studies have demonstrated the production of both immature and 
mature neurons that migrate towards the striatum following a stroke. Ischemia-
induced neurogenesis was first documented in the hippocampus 1998 (Liu et al. 
1998). This study showed an amplification of endogenous neurogenesis following 
global ischemia, but did not show any replacement of the CA1 pyramidal cells 
that are lost in ischemia. Similar amplifications of neurogenesis in neurogenic 
regions, such as the dentate gyrus and sub-ventricular zone, have been shown 
following focal ischemia (Arvidsson et al. 2002, Parent et al. 2002). One of the 
drawbacks of endogenous neurogenesis as a therapy for stroke is that the new 
cells have limited capabilities to migrate to the site of injury. Granulocyte colony 
stimulating factor (G-CSF) has arisen as a potential therapy to allow for the 
migration of endogenous stem cells to the site of ischemic injury (Borlongan and 
Hess 2006). 
Despite studies showing the ability to recruit endogenous new neurons to the 
site of injury, there are very few studies that have been able to show new 
neurons extending axons to appropriate targets, and there has been no evidence 
of existing neurons extending axons to new neurons in vivo. Given these results, 
we are still a long way from being able to use endogenous stem cells as a viable 
treatment for stroke injury. 
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B. Neuroprotection 
Developments in the field of stem cell research have identified an application 
of exogenous stem cells as a vehicle for neuroprotective effects. One of the 
major benefits to these studies is that this approach to stroke therapy has shown 
to provide benefits far past the 3 hour time window of current therapeutic 
approaches for stroke.  
Several labs (Cui et al. 2012, Rowe et al. 2012b, Xiao et al. 2005), have tested 
various exogenous stromal stem cells intravenously in rodents after an induced 
stroke. These studies have revealed the potential for these types of treatment to 
provide multiple benefits, including reduced stroke volumes, improved functional 
outcomes, and an extended time window for treatment – up to 48 hours following 
stroke onset. These studies in rodent models of stroke show great promise for 
future stroke therapies, due to their ability to improve stroke outcome and 
recovery, and most importantly, do so at a time point later than any currently 
available treatments.   
Recent studies have focused on more specific cell types or stem cell 
populations that have been administered. Various mechanisms of delivery 
including intravenous (IV), intra-arterial (IA), and direct injection into the brain 
have been attempted. IV delivery of exogenous stem cells is desirable because it 
is the least invasive of all administration techniques. One drawback to this 
method is that many of the injected cells end up being caught in peripheral 
organs such as the liver, spleen and lungs. In phase I and II clinical trials, IV 
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administration of autologous mesenchymal stromal cells were shown to be safe 
in both the short and long term (Bang et al. 2005a, Lee et al. 2010). IA delivery is 
more invasive, infusing cells directly into the artery that is perfusing the ischemic 
tissue. The benefit of this method is that it allows the cells to bypass any 
peripheral organs and go directly to the site of injury. Some concerns with this 
method of delivery are the potential for the injected cells to form microvascular 
occlusions, thus worsening the ischemia and resulting in higher mortality rates (Li 
et al. 2010b, Walczak et al. 2008). Finally, direct intra-cerebral injection is highly 
invasive and carries many risks, such as initial human studies showing adverse 
side effects such as seizures, subdural hematoma and worsening of motor 
function(Kondziolka et al. 2005a, Savitz et al. 2005).  
Despite the wealth of research in the field of therapeutic applications of stem 
cells, there is no unified theory for the mechanism of action exhibited by these 
cells. One of the longest held views on the mechanism of action of exogenous 
stem cells as a treatment for stroke is that administered cells migrate to the site 
of injury and are able to replace diseased and dead endogenous cells by 
engraftment and differentiation into functional neural and glial cells. Support for 
this theory comes from a number of studies in animal models, such as one by 
Hayase et al.,  (2009) in which stem cells were injected into the cortex three days 
after stroke onset, and were found in the brain 100 days later, with evidence of 
projections and expressing positive markers for glutamatergic, dopaminergic, and 
  8 
GABAergic neurons. The animals that were injected with these cells also showed 
significant functional recovery.  
The evidence for engraftment and transdifferentiation, however, has been 
heavily scrutinized, and many studies have provided evidence against this theory 
of stem cells as the sole mechanism of action. It has been shown that adult 
hematopoietic stem cells cannot differentiate into functional neurons. One of the 
pitfalls many studies face is that they look for neuronal markers for evidence of 
transdifferentiation, but do not test the engrafted cells for functionality. A study by 
(Roybon et al. 2006) showed that when hematopoietic stem cells were grown in 
culture, they were able to differentiate into neuron-like cells, but these cells were 
not capable of producing an action potential. When these same cells were 
transplanted into the brain, there was no evidence of a neuronal phenotype. 
Instead, the injected cells differentiated into microglia, or died shortly after 
transplantation. This study, and many others like it (Xiao et al. 2005), have 
shown that while there are often significant improvements in stroke outcome 
following stem cell administration, and engraftment and transdifferentiation may 
not be the mechanism by which these cells are acting. 
An emerging theory as to the mechanism of action of therapeutic stem cells 
has arisen from a large number of studies that have shown a beneficial effect of 
the administration of stem cells following stroke, but have found little evidence of 
extensive engraftment or cell replacement in the brain. It has been suggested 
that the mechanism by which exogenous stem cells act is by altering the local 
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immune response at the site of injury and modulating chronic inflammation. The 
tissue surrounding any type of brain injury has been shown to be highly pro-
inflammatory, with increases in pro-inflammatory cytokines such as IL-1a, IL-1b, 
IL-6, and TNF-α upregulated at 48 hours following injury (Harting et al. 2008).  
Several studies have shown that administration of exogenous stem cells into a 
stroke animal have resulted in a reduction in inflammatory cytokines, as well as 
an upregulation in anti-inflammatory cytokines. (Liu et al. 2009) showed that 
MSC that were injected into the cortex following stroke in a rat model not only 
decreased the infarct size, but that IL-10 was up regulated and TNF-α was down 
regulated following MSC administration, suggesting an anti-inflammatory effect of 
the MSCs.  
An in vitro study of MSCs grown in contact culture with NSCs showed an 
increase in IL-6 production as well as a decrease in apoptosis. These results 
suggest that the direct implantation of MSCs that come into contact with 
endogenous NSCs stimulates the local immune response through NFkB activity 
(Walker et al. 2010). This result was not replicated in in vitro studies without cell-
cell contact. 
When looking to apply cell therapies in the clinic, opting for less invasive 
therapies is preferable. IV and IA administration of stem cells have been studied 
in many animal models of stroke and brain injury. These studies generally show 
little to no cell engraftment in the brain, but do show decreases in infarct volume 
as well as improvements in functional outcome measures. One common 
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observation is that this type of administration results in what is known as the 
‘pulmonary first pass effect’ (Fischer et al. 2009). IV administration results in the 
majority of injected cells becoming caught in the lungs, spleen, kidney, and liver. 
Yet significant infarct reduction and improvement in functional recovery has been 
repeated in numerous studies.  
One suggested mechanism of action in these instances is modulation of the 
systemic immune response which stimulates anti-inflammatory and pro-survival 
responses that ameliorate stroke injury. There is evidence that systemically 
administered stem cells interact with immune cells in multiple organ systems. For 
example, stem cells that become caught in the lungs have been shown to 
interact with pulmonary macrophages and modulate the systemic inflammatory 
response (Nemeth et al. 2009). As previously discussed, modulation of the 
inflammatory response is key in improving stroke outcome. It has also been 
shown that IV administration of MSCs results in a decrease in the pro-
inflammatory cytokines TNF-α and IL-6 in the serum, as well as an increase in 
the anti-inflammatory cytokine IL-10 (Nemeth et al. 2009). Systemically 
administered stem cells can also interact with splenocytes to have an effect on 
the overall immune response following stroke. A study by (Lee et al. 2008), 
systemically administered NSCs in ischemic rats, resulting in improved functional 
outcomes and reduced infarct size, though very few transplanted cells were 
found in the cortical tissue. Cytokine analysis showed a decrease in the pro-
inflammatory cytokines TNF-α and IL-6 in both the brain and the spleen, and 
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histology showed a large number of NSCs present in the splenic tissue. Stroke 
animals receiving NSCs that had splenectomies did not show any improvement 
following ischemic injury, providing a strong case for the necessity of NSC 
interaction with splenocytes for improved stroke recovery. 
Alterations in the pro- and anti-inflammatory cytokine profiles of stroke animals 
as a result of stem cell therapy may be crucial to ameliorating stroke deficits. In 
addition to affecting the inflammatory profile, stem cells can secrete cytokines 
that promote angiogenesis and neovascularization (Neuhoff et al. 2007). It is, 
perhaps, by altering the local and systemic immune system that provides the 
benefit that is seen following stem cell administration, even when no engraftment 
occurs.  
STEM CELL TRANSPLANTATION FOR TREATMENT OF STROKE 
A. Goals for stem cell transplantation 
In order for cell transplantation to successfully provide therapy, cells must 
either cross the blood brain barrier and influence the local stroke milieu, influence 
the systemic immune response, or replace cells lost to ischemia, resulting in 
improved outcome and reduced injury. If used to generate new neurons, these 
new neurons must mature, form synaptic connections and not die. If used for 
neuroprotection, then it will be important to understand if it is needed for them to 
cross the blood brain barrier, as well as understanding the effect of first pass 
through the lungs and the liver. It will be important to know the drawbacks and 
advantages of each type of cell administration: IV, IA, and direct injection. It must 
  12 
also be determined whether or not it is better to use autologous cells which likely 
will require time before given to a stroke patient or to have banked cells that can 
be given immediately.  
B. Stem cell types 
Embryonic Stem Cells (ESCs) 
Embryonic stem cells (ESCs) have long been considered the gold standard for 
pluripotency, and are considered ideal for therapy due to their ability to 
differentiate into any cell type including neurons and glia. One of the major 
drawbacks of using this cell type is that they can create teratomas if they are 
injected in an undifferentiated state (Seminatore et al. 2010). The post-ischemic 
environment has been indicated as a cause of teratoma formation from 
undifferentiated cells, yet hyperproliferation has also been documented in cells 
that were injected at a later stage of differentiation, and this effect is independent 
of the surrounding environment (Seminatore et al. 2010). It is very difficult to 
create a homogenous culture of ESCs that are completely without 
undifferentiated cells that may cause teratoma formation. It is critical that any 
graft used for therapy in humans be devoid of undifferentiated cells. These cells 
also are surrounded by political and ethical concerns that have limited research 
and would make them more difficult to apply to the clinical setting.   
Several studies have shown ESCs transplanted into the ischemic brain that 
exhibit neuronal markers and synaptic connectivity. (Buhnemann et al. 2006) 
injected ESC derived neural precursors into mouse cortex and found the 
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transplanted cells survived up to 12 weeks, although the number of surviving 
cells was much lower than the number that were injected. The surviving 
transplanted cells differentiated into glial cells and neurons of several different 
neurotransmitter producing types. Similar evidence of the functionality of 
transplanted ESCs has been shown by Takagi et al. (2005), in which NPCs 
derived from monkey ESCs were injected into MPTP monkeys – a primate model 
of Parkinson’s Disease. They found that the transplanted cells were able to 
function as dopaminergic neurons. In addition, animals receiving the cell 
transplant exhibited improved behavioral recovery. A recent study showed that 
transplantation of ES-NPCs into healthy murine cerebral cortex results in 
manifestation of dendritic and axonal connections. In addition, these transplanted 
cells did not form inappropriate connections (Ideguchi et al. 2010).  
Inducible Pluripotent Stem Cells (iPSCs) 
The reprogramming of adult fibroblast cells to exhibit properties of embryonic 
stem cells, has led to the generation of so-called inducible pluripotent stem cells  
(iPS cells). Until recently, issues surrounding immune rejection, potential for the 
formation of tumors, and ethical concerns decreased the attraction of pursuing 
stem cell transplantation as a therapy for stroke. However, landmark studies by 
Yamanaka identifying iPS, or inducible pluripotent stem cells, provided a 
promising new direction for stem cell therapy. iPS cells are derived by genetically 
reprogramming adult fibroblasts into an embryonic stem cell-like state by 
expressing a set of genetic factors that allow the cells to exhibit pluripotency 
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(Takahashi et al. 2007, Yu et al. 2007). These cells are being developed in 
several therapeutic settings due to their ability to differentiate into cells that are 
characteristic of all three embryonic germ layers. An additional benefit of these 
reprogrammed cells as cell therapies is that fibroblasts from patients can be 
taken and reprogrammed, thus eliminating the need for immune suppression.  
Since the initial study by Yamanaka and his colleagues, many studies have 
emerged on the production of iPS cells using various combinations of factors and 
generating iPS cells from various tissue sources. Due to the limited availability of 
these cells, very few stroke-specific studies have been conducted using iPS cells 
as therapy. Kawai et al., (2010) studied the administration of iPS cells in a rodent 
model of stroke, and found severe teratoma formation in the brains of both the 
stroke and sham operated animals.  
These results show similar caveats to the use of ESCs for therapy – i.e., the 
administration of undifferentiated iPS cells may result in teratoma formation, 
making them unsuitable for therapy in their undifferentiated state. A recent study 
has demonstrated that the epigenetic changes induced in the process of 
generating iPS cells can induce immune rejection (Pera 2011). Whether this will 
occur in clinical practice, however, remains unknown. While iPS cells can be 
expanded and can be used to produce various cell types, it remains difficult to 
generate highly purified cell populations and even when directed to differentiate 
into specific neuronal populations there is still a significant potential to form 
teratomas in vivo (Kawai et al. 2010).  
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Neural Stem Cells (NSCs) 
Another type of cell that has been investigated for its therapeutic properties is 
the neural stem cell (NSC). These cells can be isolated from several regions (the 
sub-ventricular zone and the sub-granular zone) in the central nervous system of 
embryos as well as in adults and can be grown and expanded in culture as 
neurospheres (Arvidsson et al. 2002). Unlike ESCs, NSCs are not pluripotent, 
but they can differentiate into many, but not all, types of CNS cells. They have 
been shown to differentiate into neurons, astrocytes, and oligodendrocytes. 
While some studies have used grafts of exogenous NSCs, others have 
attempted to recruit endogenous NSCs to the site of injury as a potential therapy. 
A study by Li et al., (2010a) demonstrated that the endogenous NSCs in the 
adult brain that are activated by ischemia are necessary for neuroprotection of 
the ischemic brain. By inhibiting cell proliferation in the brain following ischemia, 
they found a large increase in infarct size and functional deficit, indicating a 
crucial role for endogenous NSCs in stroke recovery. Another study has shown 
that the intra-ventricular administration of NSCs results in improved functional 
recovery at 28 days following stroke, and also found that NSCs expressing HIF-
1a further improved recovery (Wu et al. 2010). While many studies have shown 
the potential therapeutic benefit of both endogenous and transplanted NSCs, one 
of the limiting factors of this type of treatment is the poor survival rate of 
transplanted cells. It has been reported that as little as 1-3% of the transplanted 
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cells survive, and an even smaller percentage have been shown to differentiate 
into neurons (Toda 2001). Despite the low survival rate, studies of NSCs have 
shown consistent therapeutic benefits in animal models of ischemic stroke.  
Adult tissue-derived stem cells 
One of the most popular sources of cells for cell-based therapy is adult tissue-
derived stem cells. These include, but are not limited to, bone marrow derived 
stem cells, umbilical cord blood derived stem cells, and teratocarcinoma cells. 
Bone marrow derived cells are among the most commonly researched adult stem 
cell types, and were identified as potential therapeutic targets due to the 
endogenous behavior of bone marrow cells.  
Marrow Stromal Cells (MSCs) are a type of bone marrow derived stem cell 
that have been widely studied for their therapeutic benefits. It has been 
demonstrated that these cells migrate towards tissue injury signals in vitro 
(Menon et al. 2007), however, in vivo models have shown a very poor survival 
rate of transplanted MSCs (Coyne et al. 2006). Despite the low rate of cell 
survival following transplantation, many studies have shown improved outcome 
following ischemic injury after the transplantation of MSCs (Willing et al. 2003). A 
second type of bone marrow derived stem cell is multipotent adult progenitor 
cells (MAPC). These cells were originally thought to be superior to MSCs due to 
their ability to generate functional cell types from all three embryonic germ layers, 
including neurons with mature electrophysiological properties (Serafini et al. 
2007). However, studies of transplantation of MAPCs resulted in improved 
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recovery from ischemia (Zhao et al. 2002), but did not show robust  evidence of 
engraftment (Burns et al. 2006).  
Another type of adult-derived stem cells are teratocarcinoma cells, which are a 
variant of embryonic stem cells that have been derived from an immortalized cell 
line of germ cell tumors. These cells are able to differentiate into a pure 
population of neurons when exposed to retinoic acid (Damjanov 1990). These 
cells have been tested in clinical trials (Kondziolka et al. 2000) as a treatment for 
stroke and shown to be safe as well as exhibit engraftment as postmitotic 
neuronal cells. The patients in this study showed a small amount of functional 
improvement, but this improvement was not found to be statistically significant 
(Kondziolka et al. 2005b). Although these cells avoid any ethical concerns such 
as those that arise from ESC use, questions of safety will always be a concern 
with this cell line, due to the tumorigenic nature of the donor cells.  
A promising source of therapeutic adult-derived stem cells is umbilical cord 
blood, which has been shown to be rich in stem cells, varying fractions of which 
have been tested in animal models of ischemic stroke as a potential therapy. 
Administration of these cells has shown a dramatic decrease in infarct size as 
well as improved functional recovery (Xiao et al. 2005, Rowe et al. 2012a, Cui et 
al. 2012). A recent study combining the administration of Simvastatin in addition 
to human umbilical cord blood stem cells in a rat model of stroke showed an 
increase in injected cells migrating into the brain. As a result, they showed 
increased neural plasticity and improved neurological outcome (Cui, et al., 2012). 
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Many studies using umbilical stem cells show little to no evidence of surviving 
transplanted cells in the brain following systemic delivery, suggesting that cell 
replacement is not the mechanism of action for the beneficial effects of these 
cells.  
An extension of the concept of reprogramming somatic cells to become iPSCs 
is the method of direct reprogramming to generate neurons directly from adult 
fibroblasts. Recent studies have demonstrated the production of several neuronal 
types through the approach of direct reprogramming (Meissner, Wernig and 
Jaenisch 2007). Since these cells do not re-enter the cell cycle, there is no 
potential to form tumors. One of the limitations of using these types of cells as a 
therapy for stroke is that it is difficult to generate a sufficient number of cells, 
generation of directly reprogrammed cells takes time, and therefore may not be 
produced in time for administration when needed. 
As described previously, many types of adult derived stem cells exhibit an 
innate tropism towards a site of injury. Some researchers are harnessing the 
ability of these cells to migrate towards injury sites and reprogramming them to 
act as vehicles of gene therapy. Adult stem cells can be made to deliver 
therapeutic molecules that are anti-inflammatory, pro-angiogenic, pro-survival, or 
anti-apoptotic (Muller, Snyder and Loring 2006). MSCs have been modified to 
express PlGF (Placental Growth Factor), which is angiogenic to impaired non-
neural tissue. Stroke animals that received MSCs expressing PlGF showed a 
decrease in infarct size, as well as an increase in functional recovery and 
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angiogenesis at the site of injury (Liu et al. 2006). Another study utilized MSCs 
expressing Ang-1, and found that the stroke animals that received the genetically 
modified cells showed an increase in angiogenesis and neovascularization, 
specifically at the border of the infarct area, as well as overall increased cerebral 
blood flow and a decrease in infarct size (Onda et al. 2008). These studies 
suggest that gene therapy using stem cells as vehicles may provide added 
benefit and improved outcome following ischemic stroke.  
 
CLINICAL TRIALS 
The promising results of preclinical research in this field have prompted a 
large number of preliminary clinical studies to be launched in recent years. One 
of the earlier clinical trials to investigate the efficacy of stem cells as a treatment 
for stroke tested the safety and efficacy of mesenchymal stem cells (MSCs) in a 
randomized and controlled phase I/II trial (Bang et al. 2005b). This study 
recruited patients that had acute cerebral infarction within the area of the middle 
cerebral artery, and aspirated bone marrow from these patients one week 
following stroke onset. MSCs were isolated from the marrow and administered 
intravenously between five and seven weeks following stroke. Short term follow 
up showed no adverse effects from the cell administration, and functional 
recovery improved in patients receiving MSC therapy according to the Barthel 
Index and the modified Rankin Score. A long term follow up study of the same 
patients confirmed that intravenous delivery of MSCs is safe, and that some 
  20 
patients may derive a functional benefit, though they noted that functional 
improvement was associated with serum levels of stromal cell-derived factor-1, 
as well as the involvement of the subventricular region of the lateral ventricle 
(Lee et al. 2010). 
A second clinical trial also tested the effects of bone marrow-derived 
mononuclear cells as a treatment for stroke (Moniche et al. 2012). In this study, 
patients were administered intra-arterially between 5 and 9 days following stroke. 
This study found no adverse effects related to the cell transplantation. However, 
there was also no significant neurological improvement at 180 days following the 
cell administration. There was a trend towards functional improvement in the 
Barthel Index correlating with the number of CD34+ cells that were injected.  
Of the many ongoing clinical trials in this field, the majority focus on 
determining the safety and efficacy of bone marrow derived stem cells as a 
treatment for stroke. Other cell types being studied include: modified stem cells, 
umbilical cord blood derived stem cells, and adipose derived stem cells. The 
majority of the ongoing clinical trials are administering the therapeutic cells 
systemically either via IV or IA administration , as this method of delivery is the 
least likely to cause complications. The studies encompass therapies for both 
chronic and acute ischemic stroke. A summary of current ongoing stem cell trials 
for stroke can be found at the website ClinicalTrials.gov and are listed for 
convenience below in Table 1. As the present time the results of these current 
studies have yet to be reported and are anxiously awaited. 
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CONCLUSIONS 
 There is a wealth of evidence supporting the use of stem cell therapies for 
ischemic stroke, but the mechanisms by which these cells exert their 
neuroprotective effects have yet to be fully elucidated. It must also be determined 
if different cell types have distinct mechanisms of action, as well as what risks 
are posed by each cell type and delivery method. With a more complete 
understanding of the mechanisms by which cell based therapies are able to 
ameliorate stroke injury, we will be able to successfully transition these therapies 
from the lab bench into the clinic.  
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Chapter 2 
 
Amelioration of Ischemic Brain Injury with  
Human Umbilical Cord Blood Stem Cells:  Mechanisms of Action 
 
 
ABSTRACT 
Despite the high prevalence and devastating outcome of ischemic stroke, 
there remain few options for treatment following stroke onset. The treatments 
that are currently available remain limited both in the time window following 
stroke in which they are effective, as well as their success in ameliorating stroke 
injury in the brain and limiting functional impairment. Current therapies for stroke, 
such as tissue plasminogen activator (tPA) are only effective up to 4.5 hours 
following stroke onset. We have tested a human umbilical cord blood-derived 
stem cell line that has shown both a significant reduction in stroke infarct volume 
as well as improved functional recovery following stroke in the rat when 
administered 48 hours following stroke onset. In the present study we have 
compared high vs. low passage non-hematopoietic umbilical cord blood stem 
cells (nh-UCBSCs) to determine whether highly expanded nh-UCBSCs are as 
therapeutically effective as low passaged cells, and their mechanisms of action. 
Using the middle cerebral arterial occlusion (MCAO) model of stroke in Sprague-
Dawley rats, we administered nh-UCBSC by intra-venous administration two 
days following stroke induction. These human cells were injected into rats without 
any immune suppression, and no adverse reactions were detected.  Both 
behavioral and histological analyses have shown that the administration of these 
cells reduces the infarct volume by 50% as well as improve the functional 
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outcome of these rats following stroke for both high and low passaged nh-
UCBSC. The brain transcriptome was compared between normal rats, and those 
with ischemic brain injury, and injury with nh-UCBSC treatment using next 
generation RNAseq analysis. Differences in the brain transcriptome revealed that 
ischemic brain injury was associated with significant increases in transcripts 
related to macrophage, T cell, and microglia function.  Flow cytometry analysis of 
immune cells present in the brains of animals, in each of these three groups, 
confirmed infiltration of macrophages and T cells consequent to ischemia 
reduction to normal levels with nh-UCBSC treatment.  Flow cytometry also 
revealed a restoration of normal levels of microglia in the brain following 
treatment. Overall, these data show a blunting of immune cell migration and 
activation that are typically activated in the brain following stroke, suggesting that 
nh-UCBSCs may act by inhibiting immune cell migration into the brain from the 
periphery, and possibly by inhibition of immune cell activation within the brain. 
Non-hematopoietic umbilical cord blood stem cells exhibit great potential to 
provide a novel therapy for stroke with no known ill-effects, and are effective at 
later time points following stroke than methods that are currently available in the 
clinic.  
 
 
INTRODUCTION 
 
Stroke is the fourth leading cause of death and the primary cause of long-
term disability in the United States. Each year, more than 795,000 people have a 
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stroke, the majority of which are first time occurrences (Go, et al. 2014). Among 
all types of stroke 87% are ischemic strokes, which are caused by either a 
transient or permanent reduction of blood flow and oxygen supply to the brain, 
resulting in death of neural tissue. This reduction is most commonly due to 
arterial blockage due to clotting or narrowing of the blood vessels that supply the 
brain.  
Despite the high prevalence of stroke there are very few options for 
treatment in existence today. One of the primary therapies available to stroke 
patients is tissue plasminogen activator (tPA), which is a thrombolytic agent, and 
is only effective within 4.5 hours following stroke onset (Lansberg, et al. 2009). 
Due to the narrow therapeutic time window, only 3-5% of stroke patients are able 
to receive this treatment (Go, et al. 2014). As yet, there are no therapies that are 
able to provide neuroprotection to the affected brain tissue following stroke.  
Cell-based therapies are emerging as a promising therapy that can be 
administered within the first few days (compared to hours) following stroke onset. 
A variety of stem cell types have been tested as potential therapies for ischemic 
stroke, each with unique advantages and limitations. Embryonic stem cells 
(ESCs) are considered the gold standard for pluripotency as they are able to 
differentiate into any cell type. However, the administration of undifferentiated 
ESCs leads to teratoma formation, and it is extremely difficult to create a 
homogenous ESC culture that is completely free of undifferentiated cells 
(Seminatore, et al. 2010). ESCs that have been transplanted into the brain 
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following stroke have been shown to exhibit neuronal markers (Buhnemann, et 
al. 2006; Takagi, et al. 2005), though studies have not found these transplanted 
cells to exhibit functional connections (Ideguchi, 2010).  
Induced pluripotent stem cells (iPSCs) are another potential cell-based 
therapy for ischemic stroke. These cells are adult fibroblasts that are genetically 
reprogrammed into an embryonic stem cell-like state (Takahashi, et al. 2007; Yu, 
et al, 2007). One of the primary benefits of these cells is the elimination of the 
need for immune suppression, as the fibroblasts can be taken from the patient 
needing the treatment. Unfortunately, studies have shown that despite this, 
epigenetic changes to these cells can still result in immune rejection (Pera, et al. 
2011). Another drawback of using reprogrammed adult fibroblasts is the 
possibility of teratoma formation following administration (Kawai, et al. 2010). 
Neural stem cells (NSCs) can be isolated from the subventricular zone and 
subgranular zone in both embryos and adults (Arvidsson, et al. 2002), and are 
not pluripotent, but are able to differentiate into many types of CNS cells. 
Administration of NSCs following stroke did show improvement in stroke 
outcome, though the survival rate of the administered cells was extremely low – 
at around 1-3% of transplanted cells (Wu, et al. 2010).  
Several types of bone marrow derived stem cells are being studied as 
potential stroke therapies. Marrow stromal cells (MSCs) have been shown to 
migrate towards a site of injury in vitro (Menon, et al. 2007), though these cells 
show poor survival rates when administered in vivo (Coyne, et al, 2006). 
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Multipotent adult progenitor cells (MAPCs) are also bone marrow derived, and 
have been shown to be able to regenerate into neurons (Serafini, et al. 2007). 
Administration of these cells has been shown to improve recovery following 
stroke (Zhao, et al. 2002), though they also show low engraftment rates and have 
the potential for teratoma formation (Burns, et al. 2006). 
Cells derived from the mononuclear fraction of human umbilical cord blood 
(UCB) are becoming prominently studied as a potential therapeutic agent for 
stroke because they overcome many of the limitations presented by the other 
cells types discussed above. Many studies have shown that administration of 
varying fractions of UCB provides an improvement in stroke outcome when 
administered within 72 hours following stroke (Rowe, et al. 2012; Cui, et al, 2012; 
Boltze, et al, 2012).  A limitation of UCB is that the quantity available from each 
donor may require multiple donors for treating an individual patient. In a previous 
study we addressed this issue by identifying and characterizing CD34-negative 
stem cells within UCB that could be expanded in vitro (Xiao et al., 2005).  This 
cell fraction also expresses the stem cell markers Sox-2, Rex-1, and Oct-4 (Xiao, 
et al., 2005). We refer to these cells as non-hematopoietic umbilical cord blood 
stem cells (nh-UCBSCs).  We demonstrated that systemic administration of nh-
UCBSCs 48 hours after ischemic brain injury could significantly reduce infarct 
volume and ameliorate associated neurological deficits.  In the current report we 
describe mechanisms of action underlying the neuroprotective effects of nh-
UCBSCs in treating ischemic brain injury.  
  28 
 
MATERIALS AND METHODS 
 
Animal Subjects 
Female Sprague-Dawley rats, 275-300 grams, from Charles-River Laboratory. All 
animals were housed and maintained according to the guidelines of the 
University of Minnesota Animal Care and Use Committee (IACUC). Clean 
bedding and fresh food and water was regularly provided by Research Animal 
Resources (RAR) staff. All animals received regular veterinary care by RAR. 
 
Surgical Induction of Stroke 
Rats are anesthetized with Ketamine/Xylazine cocktail (0.85mL/kg; 75mg/ml 
Ketamine, 10mg/mL Xylazine) intramuscularly. The rat’s head is stabilized in a 
Koph head-holder in a supine position after the fur of the neck area is shaved 
and sterilized. Midline skin in the neck is incised and retracted laterally to expose 
subdermal structures. The right common carotid artery is exposed after the 
digastric and sternomastoid muscles are retracted. After carefully separating the 
right vagus nerve, the right common carotid artery (rCCA) is traced distally to its 
bifurcation, the superficial branch of which is the external carotid artery (ECA). 
While tracing distally along it, the endpoint is reached which branches out into 
the superior thyroid artery, external maxillary artery and terminal lingual artery. 
The right ECA is freed by cauterization and cut at this point, so that ECA stem is 
long enough to be able to introduce the thread occluder for the temporary 
ligation. The right internal carotid artery (rICA) has an extracranial branch before 
it enters the cranium - the pterygopalatine artery - which is temporarily ligated for 
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a complete ischemic lesion. The rECA is cut at its distal stem so that a silicon-
coated surgical thread can be inserted into its lumen. The thread is inserted into 
the bifurcation, and up into rICA. The occluder is kept in place for 1 hour before 
removal. The open arteries are then cauterized, the wound closed, and the 
animal monitored until fully sternal and recovered.  
 
Laser Doppler 
In order to ensure that the MCA occlusion is having the same effect on all 
animals, we used MoorLab laser doppler to monitor blood flow of the right 
hemisphere of the brain (Moor Instruments; Wilmington, DE). Once baseline 
blood flow is established, the MCA is occluded as described above. Blood flow 
must be maintained at 20-25% of baseline during the occlusion period in order 
for individual animals to be kept in the study.  
 
Behavioral Analysis  
The Neurological Severity Score (NSS) (modified from De Ryck) were used to 
evaluate neurological deficit following MCAO. The NSS test consists of eight 
subtests evaluating motor and sensorimotor function of the animals’ limbs. Left 
and right side limbs are each scored as either 2 (normal function), 1 (impaired 
function), or 0 (unable to perform). The scores from these subtests were tallied 
for the right side and left side limbs. The animals’ functional score is presented 
as a ratio of the total score of the left side limbs to the right side limbs.  
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Measurement of Infarct Size 
PFA-perfused brains were parrafinized and cut into 5µm sections by microtome 
and mounted sequentially on gelatin-coated slides. A 5µm slice was mounted 
every 25µm throughout the length of the brain, slicing rostral to caudal. The 
slides were then stained with Hematoxylin and Eosin to determine infarct size. 
Briefly, slides were deparaffinized through 3 changes of xylene (3 minutes each), 
hydrated through graded alcohols for 30 seconds each, and then run through a 
gentle flow of tap water for 1 minute. Slides were stained with hematoxylin for 3 
minutes, rinsed with water for one minute, acid water for 15 seconds, water for 
one minute, ammonium water for 15 seconds, tap water for one minute, and 
Eosin for 1 minute. Slides were then dehydrated through graded alcohols to 
100% alcohol, and cleared in 3 changes of xylene (30 seconds each). Slides 
were coverslipped with Permount and allowed to air dry. Images of sequential 
sections from each brain were collected using a Nikon Eclipse E600 equipped 
with SPOT (Diagnostic Instruments Inc., Sterling Heights, MI). ImageJ (NIH) was 
used to obtain volume measurements.  Infarct volume was measured by 
quantifying the infarct area of each mounted slice, and then multiplying the area 
measurement by the section thickness to create a measure of volume for that 
section. The volume of the infarct for all sequential sections was summed to 
obtain the total infarct volume.  
 
Preparation and Administration of nh-UCBSC 
Human Umbilical Cord Blood Stem Cells (UCBSC) were obtained and grown as 
described in our previous publications (Xiao, et al. 2005). The cell suspension 
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injectate was made immediately before use with a final concentration of 2x106 
cells/mL in sterile saline. Those animals chosen randomly to be in the treatment 
group received 1 million cells in 0.5mL sterile saline by way of the saphenous 
vein. Injected animals were briefly anesthetized with isofluorane gas for the 
duration of the injection (<1 minute), and monitored until fully awake and sternal. 
 
Flow Cytometry 
Brain mononuclear cells were isolated using a density gradient as described in 
Pino, et al. (2011). Briefly, whole brains were homogenized and suspended in a 
30% Percoll solution with media. This mixture was gently pipetted over 1mL of 
70% Percoll to create the density gradient. After centrifugation, the cell interface 
was removed. Once the mononuclear fraction was isolated and counted, a 96 
well plate was seeded with 5X105 cells per well. The seeded cells were then 
blocked using a mouse anti-rat Fc block for 5 minutes at 4º C. Cell surface 
antibodies were then added and incubated for 15 minutes at 4º C. Wells were 
then spun down and washed three times with PBS (w/2% FBS). Cells were fixed 
using the cytofix/cytoperm kit (BD Biosciences) according to manufacturer’s 
directions. Cells were washed again three times. Intracellular antibodies were 
added and incubated for 20 minutes at 4ºC. Cells were washed three more times, 
and resuspended in FACS buffer with AccuCount beads (Spherotech; Lake 
Forest, IL) for analysis on the flow cytometer (BD FACSCanto). Cells were 
stained using CD45 and CD11b (BD Biosciences; San Jose, CA) to identify 
microglia and macrophages, CD3, CD4, and CD8a (eBiosciences; San Diego, 
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CA) to identify T cells and their subtypes. Tregs were identified by the expression 
of CD3 (+) CD4 (+) FoxP3 (+) on brain immunocytes. CD25 was used as an 
activation marker to identify activated CD3+ T lymphocytes. Mature B cells were 
identified using a triple color reagent to select CD3-CD161-CD45RA+ cells (ABD 
Serotec, Kidlington, UK). Isotype specific antibodies were used for all dyes and 
panel combinations to control for nonspecific antibody binding. Immunostained 
cell populations were analyzed using FlowJo software (TreeStar; Ashland, OR).  
 
RNA isolation  
RNA was isolated from the right cerebra of all animals using a modified 
method of the RNeasy Plus RNA Isolation Protocol (Qiagen; Germantown, MD). 
Tissue was disrupted using a mortar and pestle pre-cooled with liquid nitrogen. 
600 µl RLT buffer + beta-mE were added to each sample and the sample was 
further homogenized using an electronic pestle. Each sample was run through a 
28G needle to confirm homogenization. Once fully homogenized, the samples 
were run through gDNA Eliminator Mini Spin Columns (Qiagen; Germantown, 
MD) for two minutes at 10,000RPM or until the column was dry. 600 µl of 70% 
ethanol was added to each sample. Samples were then run through RNeasy Mini 
spin columns (Qiagen; Germantown, MD) two times for 15 seconds at 
10,000RPM. Flow through was discarded. 700µl of RWT buffer was added to the 
RNeasy spin column, and the flow through was discarded. 500µl RPE buffer was 
added to the RNeasy spin column and the flow through was discarded. This step 
was repeated a second time. 50µl RNase-free water was added to the spin 
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columns and let sit for 10 minutes. Columns were then spun down and RNA was 
measured using a spectrophotometer.  
RNAseq 
RNA from the three experimental groups (control, stroke, stroke + UCBSC 
treatment) was submitted for sequencing at the University of Minnesota 
Genomics Center using the Illumina HiSEq 2000 sequencer. The gene 
expression profile for each group was analyzed using the following parameters: 
50 cycle read length; paired-end read type; 20 million reads; 50-100 nucleotide 
fragment size. Genes with significant increases in expression for the MCAO 
model (P<.01) were identified using Galaxy. A subset of genes within this group 
was identified that revealed a significant decrease in expression for the therapy 
models as compared to the stroke models. These genes were categorized by cell 
type in which they are expressed.  
 
Statistical Analysis 
ANOVA was used to determine differences between groups. P values less than 
0.05 were considered significant. Outliers in all data sets were determined using 
Grubb’s test and excluded from analysis. The Bonferroni-Holm post-hoc test was 
used to determine significance between groups. All data is plotted as means with 
SEM. Statistics were calculated using GraphPad PRISM software (GraphPad 
Software, Inc., La Jolla, CA). 
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RESULTS 
High passage nh-UCBSC administration reduces infarct volume and 
improves functional recovery 
In our previous study investigating the efficacy of nh-UCBSC in ischemic 
stroke (Xiao et al., 2005) we used cells that were passaged to generate 
approximately 8 population doublings.  In the present study we also used nh-
UCBSC at 25 population doublings to determine if the expanded cells maintained 
their therapeutic efficacy.   As in the previous study human nh-UCBSCs were 
administered intravenously 48 hours following MCAO surgery. Animals were 
sacrificed 7 days following MCAO surgery for histological analysis of infarct size 
(Fig 1A, B). Quantification of infarct size showed a significant decrease in infarct 
volume in both nh-UCBSC groups as compared to the saline treated groups (Fig 
1C). Behavioral function was assessed 24 hours and seven days following 
MCAO surgery with the Neurological Severity Score (NSS). At 24 hours following 
stroke, all treatment groups showed equivalent functional impairment. At seven 
days following MCAO surgery, the saline treated group showed no functional 
improvement.  In contrast, the nh-UCBSC treated animals showed significant 
functional improvement in the NSS test (Fig 1D).  
To determine whether the expansion of the cells diminished the 
therapeutic efficacy of nh-UCBSCs, cells at eight population doublings and 25 
population doublings were compared. There was no significant difference 
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observed between the two groups in terms of reducing infarct size (Fig 1C) and 
improving neurological functional recovery (Fig 1D). 
 
Changes in gene expression in the brain due to stroke are normalized with 
UCBSC treatment 
Next generation sequencing RNAseq was used to determine transcripts 
which have significantly altered expression in the brain seven days following 
stroke onset. A total of 240 genes showed significantly altered expression levels 
following stroke that were then normalized with nh-UCBSC treatment (Fig 2). The 
genes that increased in expression level following stroke are predominantly 
related to inflammation and immune function. The genes that decreased in 
expression following stroke are predominantly related to neuronal function.  
 
nh-UCBSC treatment reduces the number of macrophages in the brain 
following stroke 
RNAseq analysis showed an increase in the expression of several 
macrophage activation markers in the ischemic brain, 7 days following stroke, 
and the expression levels were reduced to levels seen in non-ischemic brains 
with nh-UCBSC treatment. The genes that were significantly affected were 
FABP4 - a macrophage marker (Fig 3A), LPB – LPS binding protein, which binds 
to CD14 and TLR4 on macrophages, neutrophils and dendritic cells (Fig 3B), 
CCL6 - a marker of neutrophils and macrophages (Fig 3C), A2M – a protein 
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synthesized by macrophages (Fig 3D), MPEG1 – expressed by macrophages 
(Fig 3E), WAS – expressed by hematopoietic cells (Fig 3F), CD14 – a TLR4 co-
receptor which is recognized by several pathogen associated molecular patterns 
(PAMPs) (Fig 3G), LGALS3BP – binds to macrophage associated lectin MAC-2 
(Fig 3H), and MRC2 – mannose receptor found on macrophages and dendritic 
cells, involved in the recognition of pathogens (Fig 3I).  
To determine alterations in the number of macrophages in the brain 
following ischemia and nh-UCBSC treatment, flow cytometry analysis were 
conducted. Flow cytometric analysis of brain tissue shows a significant increase 
in the number of CD11b high/CD45 high macrophages in stroke animals (Fig 4). 
This population is reduced in the nh-UCBSC treated animals, though the 
macrophage population is still significantly higher than that of the control group 
(Fig 4D).  
 
nh-UCBSC treatment reduces the number of microglia in the brain 
following stroke 
Flow cytometry was also conducted to determine the number of microglia 
in the brain after ischemia and treatment with nh-UCBSCs.  Flow cytometry 
analysis of brain tissue revealed an increase in the absolute numbers of CD11b 
high/ CD45 intermediate microglia in the stroke brain (Fig 5). This population 
decreased in cell number in the nh-UCBSC treated group, but these changes 
were not statistically significant (Fig 5D).  
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nh-UCBSC treatment normalizes the number of T cells in the brain 
following stroke 
RNAseq analysis a revealed a significant increase in the expression levels 
of several genes related to T cells and their function in the ischemic brain 7 days 
following stroke. These levels were reduced to numbers seen in non-ischemic 
brains in the nh-UCBSC treated animals. The genes that were significantly 
affected were: LCP2 – a T cell marker (Fig 6A), CD4 – a marker of Helper T cells 
(Fig 6B), GM2A – involved in T cell activation (Fig 6C), and SH2B3 – which is 
involved in T cell activation (Fig 6D).  
Flow cytometric analysis was conducted to quantify T cell infiltration into 
the brain after ischemia and treatment with nh-UCBSCs (Fig 7).  Analysis of 
CD3+ T cells showed a significant increase in the total numbers of CD3+ T cells 
in ischemic animals 7 days following MCAO surgery, and a reduction to levels 
seen in non-ischemic brains of the CD3+ T cell population in the nh-UCBSC 
treated animals at 7 days (Fig 7D).  
Flow cytometry showed a significant increase in CD4+ T cells in the stroke 
brain 7 days following MCAO (Fig 8A-C). The number of CD4+ T cells was 
reduced to non-ischemic levels with nhUCBSC treatment (Fig 9D). In contrast, no 
changes in the absolute number of CD8a+ cytotoxic T cells were observed 
among the treatment groups (Fig 8E). 
CD4+ helper T cells were co-stained with the activation marker CD25 to 
determine their activation profile during ischemic stroke and with nh-UCBSC 
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treatment (Fig 9). Flow cytometry analysis showed the absolute number of 
CD4+/CD25+ activated helper T cells significantly increased in the stroke brain at 
7 days, and the number of these cells was reduced to non-ischemic levels in the 
nh-UCBSC treated group (Fig 9D).   
CD8a+ cytotoxic T cells were co-stained with the activation marker CD25 
(Fig 10). Flow cytometry analysis showed that there was no change in the 
number of activated cytotoxic T cells in the brain across treatment groups (Fig 
10D). 
Flow cytometry was used to evaluate the presence of regulatory T cell 
population by gating for CD3+, CD4+, FoxP3+ cells (Fig 11). Quantification of 
this population shows an increase in the absolute number of regulatory T cells in 
the stroke brain 7 days following MCAO, and a reduction in the cell number of 
this population in the UCBSC treated group. These changes in the Treg 
population were not statistically significant (Fig 11D). 
 
UCBSC treatment normalized the number of B cells in the brain following 
stroke 
Flow cytometry analysis of mature B cells shows a decrease in the 
absolute number of B cells in the ischemic brain 7 days following MCAO, and B 
cells numbers increased towards the control levels of B cell numbers in the 
UCBSC treated group (Fig 12A-C). The changes in B cells numbers were not 
statistically significant (Fig 13D).  
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DISCUSSION 
Our results confirm that administration of nh-UCBSCs 48 hours after 
stroke onset significantly reduces infarct size and improves functional recovery in 
a rat model of transient focal ischemia. In order to determine the practical 
potential of transitioning nh-UCBSC therapy into the clinic, we determined that 
nh-UCBSCs do not lose therapeutic efficacy when expanded in culture for an 
extended period of time. This would allow clinicians to expand cells from one 
donor to be able to treat multiple patients – giving nh-UCBSC therapy a distinct 
advantage over other proposed cord blood cell-based therapies which require a 
new donor for each patient, and tissue matching.  
The therapeutic benefit of nh-UCBSCs when delivered at 48 hours after 
stroke is consistent with our previous study (Xiao et al., 2005) using low passage 
nh-UCBSCs.  Several groups have studied different time periods of 
administration of the mononuclear fraction of umbilical cord blood stem cells 
following stroke in order to determine the optimal therapeutic time window. 
Newcomb, et al (2006) found functional improvement and reduced infarct size 
was optimized when cells were administered 48 hours following ischemic stroke. 
They also found that the time of administration was more important to an 
improved stroke outcome than cell dose, as the optimal cell dose at any other 
time point tested did not show significant improvement. Boltze, et al. (2012) 
confirmed these results, and found that improvements in functional recovery and 
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significant decreases in infarct size were observed if the mononuclear fraction of 
umbilical cord blood stem cells were administered within 72 hours following 
stroke onset. Together these results demonstrate the ability for cell therapy to 
greatly expand on the current time window of therapy with tPA at 4.5 hours 
following stroke (Lansberg, et al. 2009).  
Our results also demonstrated that the neuroprotective effects of nh-
UCBSC administration were achieved without the utilization of any immune 
suppressive agent.  This observation is consistent with the work by Pan and 
colleagues (Pan, et al.; 2005) showing that immunosuppressive agents are not 
required for achieving therapeutic efficacy with human cord blood in cases of a 
rat model of ischemic stroke. They compared MHC levels in animals that 
received injections of UCBSCs with and without Cyclosporin A. They found that 
there was no significant difference in the expression of MHC I between groups, 
and there was no difference in cell survival between groups. Vendrame et al 
(2005 and 2006) also assessed the efficacy of the mononuclear fraction of cord 
blood in ischemic brain injury and found neuroprotective effects without the use 
of immunosuppressive compounds. Thus, immune suppression is not required to 
prevent acute rejection of nh-UCBSCs in a rat model of ischemic stroke. nh-
UCBSCs were also tested as a therapy for myocardial infarction by Chen, et al. 
(2013). This group administered the cell therapy at 48 hours following ischemia, 
and did not use any immune-suppressive agents. They found that the 
administration of nh-UCBSCs showed an increase in overall heart function and 
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preserved fiber orientation in the injured tissue area, similar to that of the sham 
operated animals.  
As cell-based therapies are gaining traction in the field of novel stroke 
treatments, multiple cell types have been tested. One of the most commonly 
investigated cell types is marrow stromal cells. These cells have been shown to 
migrate to the site of injury post-injection, though they often have very poor rates 
of cell survival. Despite this, multiple studies have observed improved stroke 
outcome following marrow stromal cell administration (Coyne, et al. 2006; Willing, 
et al. 2003). Multipotent Adult Progenitor Cells (MAPC) have also demonstrated 
an ability to improve stroke outcome following administration, though no evidence 
of engraftment into the injured tissue has been found (Zhao, et al. 2002; Burns, 
et al. 2006). Several groups have studied umbilical cord blood stem cells, and all 
have found these cells to improve stroke outcome, but as with previously 
discussed cell types, little to no evidence of engraftment of these cells in the 
injured brain tissue has been found (Cui, et al. 2012; Rowe, et al. 2012; Xiao, et 
al. 2005).  
Despite the repeated success of cell based therapies in pre-clinical trials 
the mechanism of action of these cells is widely debated. Initially, it was thought 
that by introducing stem cells to the post-ischemic brain, these new cells would 
be able to engraft into the damaged area and replace lost tissue, thus recovering 
function in the damaged areas of the brain. While some studies have shown 
evidence of these exogenous cells in the post-ischemic brain after treatment, the 
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evidence that these cells engraft to become functional cells is limited. What is 
more commonly found is that systemically administered cells show a benefit to 
stroke outcome, but are generally not found - or only found in small numbers - in 
the brain after administration (Rosado, et al. 2013). This continued finding has 
suggested that the mechanism of action is not likely due to engraftment and cell 
replacement, but due to some other mechanism. More recently, evidence has 
shown that a possible explanation for the mechanism of action of cell-based 
therapies is due to these cells exhibiting an influence on the post ischemic 
environment via the immune response and the inflammatory cascade (Walker, et 
al. 2011).  
Our analysis of mRNA in animals with ischemic stroke demonstrated a 
robust immune response in the ischemic brain associated with the infiltration of 
macrophages and T cells, as well as the proliferation of microglia. This 
observation is consistent with our current understanding of the role the immune 
system plays in the post-stroke brain. Ischemic stroke causes a disruption of the 
blood brain barrier, thus allowing peripheral immune cells to infiltrate into the 
brain and influence the local immune response. These results are congruent with 
studies in both animals and humans that have found similar increases in these 
cells in the circulating blood as well as the brain (Garcia, et al.; 1994; Urra, et al, 
2009).  
T cell trafficking into the brain has been shown at 24-48 hours after 
ischemia (Kleinschnitz, et al; 2010). This involvement of the perivascular space 
  43 
activates resident macrophages and microglia which begin to clear dead cells, 
thus increasing inflammation and stimulating the influx of more leukocytes. The 
ischemic cell death that occurs in the brain following stroke is another source of 
increased inflammatory signaling. These observations combined with studies in 
which T cell deficient mice are protected from stroke damage suggest that 
infiltration of peripheral T cells play a crucial role in the development of stroke 
injury (Kamel, et al.; 2012). T cells, but not B cells have been shown to be 
involved in the evolution of the brain infarction following stroke (Kleinschnitz, et 
al., 2010; Liesz, et al, 2011). These infiltrating T cells are a major source of IFNγ, 
which causes neurotoxicity (Yilmaz, et al; 2006; Shichita et al; 2009). The results 
of our study show the aforementioned influx of T cells in the ischemic brain. This 
influx has been reported to occur at approximately the same time period at which 
we administer nh-UCBSC treatment – following which we do not see the 
characteristic increase of T cells present in the ischemic brain. This suggests that 
the mechanism by which the nh-UCBSC treatment works involves the inhibition 
of the influx of T cells - at 48 hours following stroke – though whether this effect 
is direct or indirect has yet to be determined. If these cells are achieving the 
amelioration of stroke deficit by blunting the influx of immune cells to the brain 
following stroke, it would also prevent the propagation of an inflammatory 
microenvironment surrounding the ischemic area. 
Monocytes from bone marrow which can differentiate into either 
macrophages or dendritic cells have been shown to migrate into to infarct areas 
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in the brain following ischemic stroke (Amantea, et al. 2009). These cells are 
found in the border of the infarct area within 24 hours following stroke, and 
mature phagocytes are found directly within the infarct core (Gliem, et al. 2012). 
Studies have shown that the phagocytes found within the infarct core are 
resident microglia that have transformed into phagocytes (Tanaka, et al. 2003; 
Schilling, et al. 2003). Infiltrating peripheral macrophages are most abundant in 
the brain at 3-7 days following focal ischemia (Schilling, et al. 2003; Breckwoldt, 
et al. 2008). These results suggest that resident microglial activation precedes 
peripheral monocyte and macrophage infiltration, and that the peripheral 
macrophages are likely to contribute to the delayed phase of inflammation and 
brain injury that occurs at 3-7 days following focal ischemia. The results of our 
studies corroborate these findings, showing an influx of macrophages in the brain 
as shown by flow cytometry, as well as an increase in the expression of 
macrophage-related mRNA transcripts in our stroke animals at 7 days following 
stroke. The timing of our nh-UCBSC treatment at 48 hours following stroke 
coincides with the time period during which peripheral monocytes are infiltrating 
into the ischemic brain. As our results show a significant decrease in the number 
of macrophages in the brain at 7 days following stroke in our nh-UCBSC treated 
animals, this suggests that the treatment has some effect on the infiltration of 
these peripheral cells, thus blunting the added inflammation and injury that 
typically results from the infiltration of these cells.  
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One of the earliest cellular responses to ischemic stroke is the activation 
of resident microglia, which occurs within the first hour following stroke onset. 
There are two subtypes of activated microglia: the classically activated M1 and 
the alternatively activated M2. Ischemic neurons prime the polarization of 
microglia towards the M1 subtype, which acts as a pro-inflammatory mediator, 
and enhances neural injury. In contrast, the M2 phenotype has been shown to 
provide neural protection via the promotion of an anti-inflammatory 
microenvironment (Hu, et al. 2012). Our results show the characteristic increase 
in activated microglia in the ischemic brain 7 days following stroke. The 
population of microglial cells decreases in the brains treated with nh-UCBSCs, 
although this decrease is not significant. This decrease suggests that the nh-
UCBSC treatment either directly or indirectly ameliorated the activation of 
microglia in the post-ischemic brain.  
Our body of data suggests that the changes we observe in immune cell 
populations and their related mRNA transcripts following nh-UCBSC treatment 
following stroke show that one of the major potential mechanisms of action is the 
inhibition of the recruitment of peripheral immune cells into the ischemic brain. 
This could occur via the inhibition of MCP-1 and CCR2, both of which are 
involved in the migration of peripheral inflammatory cells following stroke. Studies 
of mice that are deficient in both MCP-1 and CCR2 have shown a significant 
reduction in infiltrating macrophages following stroke (Schuette-Nuetgen, et al. 
2012).  Another possibility is that nh-UCBSCs are able to blunt the polarization of 
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microglia and macrophages to their pro-inflammatory M1 phenotype.  Studies of 
adult marrow derived mesenchymal stromal cells have been shown to secrete 
low levels of immunomodulatory molecules such as CCL2 and IL-6 – both of 
which promote M2 macrophages (Dao, et al. 2013). Our mRNA results show an 
increase in expression of LBP (LPS Binding Protein), CD14, and TLR4, all of 
which are involved in the LPS-based activation of M1 activation. The expression 
of these genes is completely normalized following treatment with nh-UCBSCs, 
suggesting an influence on the molecular mechanism by which the M1 
phenotype is achieved.  
Our results also showed a decrease in the number of mature B cells in the 
brain following stroke, and that the number of mature B cells seemed to be 
restored to control levels following nh-UCBSC treatment. While the role of B cells 
in the development of stroke is still widely debated, regulatory B cells have been 
recently reported to have benefits in the ischemic brain 24-48 hours following 
stroke (Ren, et al; 2011). In addition, it has been shown that the absence of B 
cells leads to an increased number of activated T cells, microglia, and monocytes 
in the brain. The IV administration of B cells prior to stroke resulted in a decrease 
in infarct size as well as a decrease in the number of activated immune cells in 
the brain (Bodhankar, et al. 2013). A possible mechanism for the protective effect 
of B cells is the production of the anti-inflammatory cytokine IL-10 in the stroke 
brain (Li, et al. 2014) These results, combined with our findings suggest that at 
least some fraction of B cells play a role in protecting the ischemic brain – 
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possibly by combatting the inflammatory cascade with the release of anti-
inflammatory signals.   
The body of our work suggests that the administration of nh-UCBSC 
following stroke has a profound effect on the immune response to ischemia, 
reflected largely in the alteration of immune cell phenotypes present in the brain 
following stroke. One of the primary mediators of the release and activation of 
immune cells following brain injury is the spleen. Seifert and colleagues (2012) 
have shown that NK cells and monocytes from the spleen traffic to the brain 48 
hours following injury, and that T cells migrate to the brain by 96 hours following 
injury.  Offner, et al. (2006) reported similar findings, noting an increase in 
macrophages and CD4+FoxP3+ T cells in the blood stream at 96 hours following 
stroke, as well as a decrease in B cells, suggesting the migration of immune cells 
from the spleen to the site of injury following stroke. In addition, multiple studies 
have reported a reduction in spleen size in the acute phase of ischemic stroke, 
corresponding to the migration of immune cells to the brain, as shown by a 
decrease in CD8+ T cells in the spleen (Vendrame, et al. 2006). When these 
animals were treated with HUCBC, the spleen showed a decrease in expression 
of the pro-inflammatory cytokine TNFα, and an increase in the expression of the 
anti-inflammatory cytokine IL-10, suggesting a switch from a Th1 to Th2 
response in the spleen. A human study also showed a decrease in spleen size in 
the acute phase following stroke, followed in some cases by spleen expansion. 
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Patients that showed splenic expansion following stroke correlated to good 
clinical recovery (Sahota, et al. 2013).  
To further support the importance of the role of the spleen in the immune 
response to stroke, several studies have shown that animals that received a 
splenectomy prior to stroke showed a decreased immune response, and 
improved stroke outcome (Ostrowski, et al. 2012; Zhang, et al. 2013; Rasouli, et 
al. 2011; Fathali, et al. 2013). In addition, studies have shown that treatment with 
the mononuclear fraction of HUCB following stroke reverses the stroke related 
changes in the spleen, such as a decrease in T cell number in the spleen, 
decrease in monocytes in the blood stream, and a decrease in the macrophages 
and microglia in the brain (Golden, et al. 2012). These findings suggest that the 
inhibition of the immune response propagated by the spleen following ischemic 
injury could be crucial to ameliorating stroke related brain injury. It is likely that 
the administration of nh-UCBSCs at 48 hours following stroke plays a role in the 
inhibition of the splenic response, resulting in improved stroke outcome.  
In conclusion, our results have further demonstrated the potential for nh-UCBSCs 
to provide effective therapy for stroke when administered 48 hours following the 
onset of ischemia. Our analyses of mRNA transcripts and immune cell 
phenotyping in the post-stroke brain have shown that nh-UCBSC treatment 
ameliorates the upregulation of immune cell presence in the brain. These results 
suggest that the influx of immune cells at 48 hours following stroke play a major 
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role in the development of stroke infarction, and the blunting of these cell 
populations in the brain following stroke effectively ameliorates stroke deficit.  
 
ACKNOWLEDGEMENTS  
These studies were funded in part by NIH Grants T32 DA007097, T32 
AG029796, and R41 NS056626. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  50 
Chapter 3 
Summary, and Future Directions 
Summary of Results 
 Our body of work has shown the ability for systemic administration of nh-
UCBSCs 48 hours following MCAO in a rat to improve functional recovery and 
reduce the volume of the infarct in the rat brain. These results were achieved 
without the use of an immunosuppressive agent. Evidence from previous studies 
has shown that the mechanism  by which nh-UCBSCs exert their effects is not 
due to engraftment into existing tissue, and that the survival of injected cells is 
very low as soon as 48 hours following administration. Given this information, we 
deemed the use of an immunosuppressive agent to be unnecessary.  
 In addition, we tested nh-UCBSCs that had been expanded in culture for 
extended periods of time to determine if they are able to maintain their 
therapeutic efficacy. Our results show that extended time in culture does not 
affect the therapeutic efficacy of nh-UCBSCs to treat stroke, and that there are 
no major genetic transformations occurring following this extended time in 
culture. These results suggest that nh-UCBSCs obtained from a single donor can 
have the ability to be expanded extensively to provide treatment for multiple 
patients. The lack of need for immunosuppression in addition to the ability for nh-
UCBSCs to maintain their therapeutic efficacy following extended culture time 
gives this cell line a distinct advantage over other cell-based therapies in terms of 
clinical applications.  
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 Our study has also shown evidence that the administration of nh-UCBSCs 
acts by blunting the immune response following ischemia that typically results in 
the influx of peripheral immune cells such as macrophages and T cells. These 
infiltrating cells secrete pro-inflammatory and cytotoxic factors that contribute to 
the non-specific cell killing that contributes to the growing stroke injury in the 
brain. Our results also suggest nh-UCBSCs play a role in decreasing microglial 
activation within the brain, which is another source of the propagation of the pro-
inflammatory environment and cell killing following stroke.  
 
Limitations of Study 
 While our study utilized many of the gold standards for stroke research in 
rodents (i.e. MCAO model of stroke, NSS score for behavior, healthy rat), there 
are several limitations to the parameters of our study.  
 Firstly, our animal model utilized young, healthy female rats. While the use 
of young, healthy animals is an extremely common model for stroke research for 
several pragmatic reasons, it also presents several problems when attempting to 
translate any results gained via this model to humans. We chose to use female 
rats because despite strokes occurring in both males and females, the vast 
majority of pre-clinical stroke research is conducted in male research animals. 
There is a possibility that the estrous cycle of our female test subjects could have 
a confounding effect on our results, and it was not accounted for in this study. 
 Most strokes occur in elderly humans, but we use young animals due to 
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their good survival rates following MCAO surgery. In addition, most stroke 
patients are not healthy adults whose only health concern is the stroke itself – 
nearly all present with one, if not more co-morbidities which can contribute to the 
patients’ immune response, inflammatory state, and ability to recover 
functionally. 
 We also only used a single model of temporary focal ischemia that 
resulted in a reproducible injury in all of our animal subjects and had a high rate 
of survival. This is a practical approach for experimental studies, but does not 
reflect the highly variable nature of strokes occurring in humans. Strokes vary in 
size and duration, and some are chronic and do not result in reperfusion, as was 
the case in our current animal model. The severity of stroke could change the 
extent of the immune response, BBB permeability, and inflammatory 
microenvironment following stroke. While current research shows that nh-
UCBSC therapy to be effective at 48 hours following stroke, this time point might 
be able to be extended when being applied to instances of chronic stroke. In 
these cases, there is a prolonged state of inflammation in the brain, which could 
be benefitted by nh-UCBSC treatment. It is also possible that testing multiple 
administrations of nh-UCBSC could provide improved outcome in instances of 
chronic stroke.  
 Another limitation of our study is that we do not know if nh-UCBSCs 
indiscriminately blunt the immune response, or if it is somehow selective in only 
blunting the aspects of the immune response in stroke that are detrimental. More 
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work would have to be completed that more thoroughly characterized how each 
aspect of the immune response following stroke is being affected by the 
administration of nh-UCBSCs.  
 
Future Research Directions 
 Currently, the work presented here is providing the groundwork for several 
follow-up studies. We are aiming to reproduce the results from this study in a 
canine model of stroke. The rat and canine data will then be used to submit to 
the FDA for the approval of a human clinical trial using nh-UCBSCs as a 
treatment for ischemic stroke. We are also beginning a clinical study that looks at 
the alteration of immune cell subsets in peripheral blood following ischemic 
stroke. Once these immune cell subsets have been characterized, data will be 
collected to determine if the characteristics of these immune cell populations 
correlate to stroke severity, and could potentially be used as biomarkers for 
stroke severity and recovery. Based on our existing data, we would expect to see 
higher numbers of T cells and macrophages in the blood of patients with severe 
stroke, and smaller populations of these cells in circulation in patients with less 
severe cases. In addition, monitoring these cell populations could provide a 
valuable way to monitor a patients’ improvement following treatment.  
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Conclusion 
 Our study has provided valuable data supporting the use of nh-UCBSC as 
a cell-based therapy for ischemic stroke. In addition to strengthening the body of 
data supporting the therapeutic efficacy of these cells as a stroke treatment, we 
have also provided novel data suggesting the mechanism of action by which 
these cells provide the improved stroke outcome that has been repeatedly 
observed in pre-clinical research. This study has laid the groundwork for 
additional animal studies as well as several clinical studies, and has improved 
our understanding of how alterations in the immune response following stroke 
can have a beneficial effect on stroke outcome.  
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Figure 1. Experimental Timeline. Temporary focal ischemia was induced by MCAO surgery on 
day 0. Behavioral testing using the Neurological Severity Score (NSS) was conducted on day 1. 
On day 2, animals were given either an IV injection of 1 million nh-UCBSCs or no treatment 
without immunosuppression. On day 7 following MCAO surgery, behavioral testing was 
conducted again, and animal subjects were sacrificed for histological assessment. 
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Figure 2. Karyotyping reveals no genetic transformation of nh-UCBSCs following extended time 
in culture.  
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Figure 3. Stroke infarct volume measured by H&E staining. Staining was done 7 days following 
MCAO. Representative coronal sections of A) saline treated and B) nh-UCBSC treated MCAO 
animals. C) Quantification of infarct volume in saline treated, low passage UCBSC treated, and 
high-passage UCBSC treated animals (n=6). Low passage and high passage UCBSC groups 
have significantly smaller infarct volumes than saline treated animals (p<0.05). Average values 
(±SEM) from pooled data are presented. D) Treatment with high and low passage UCBSC 
improves functional recovery 7 days following MCAO. Behavior assessed by the Neurological 
Severity Score (NSS) is represented as a ratio of the scores of the left and right limbs. Both low 
and high passage UCBSC treated animals showed significant improvement in motor function 
compared to the saline group which showed no improvement at 7 days (p<0.05). Average values 
(±SEM) from pooled data are presented.  
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Figure 4. Scatterplot of gene expression levels across treatment groups obtained by RNASeq. 
Solid line represents gene expression levels (FPKM) in healthy control animals. Blue dots 
represent gene expression levels of stroke animals 7 days following MCAO surgery, and red dots 
represent gene expression levels of nh-UCBSC treated stroke animals 7 days following MCAO 
surgery. Genes shown in this scatterplot have significantly different expression levels (p<0.05) in 
the stroke group as compared to the healthy control group, and nh-UCBSC treatment normalized 
the expression levels of these genes. 
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Figure 5. RNA sequencing shows an increase in the expression of a number of macrophage 
markers in the ischemic brain 7 days following stroke, and a normalization of expression in the 
nh-UCBSC treated brains.  This pattern of expression if shown in A) FABP4, a macrophage 
marker, B) LBP, LPS binding protein that binds to CD14 and TLR4, C) CCL6, a marker of 
macrophages and neutrophils, D) A2M, a protein synthesized by macrophages, E) MPEG1, 
which is expressed by macrophages, F) WAS, which is expressed by hematopoietic cells, G) 
CD14, a TLR4 co-receptor, H) LGALS3BP, which binds to macrophage associated lectin, and I) 
MRC2, which is a mannose receptor found on macrophages and dendritic cells.  
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Figure 6. Number of macrophages in the stroke brain are significantly increased at 7 days 
following stroke, and UCBSC treatment reduces the total number of macrophages in the brain at 
7 days following stroke. Flow cytometry showing macrophage populations in A) healthy control 
brain, B) saline treated stroke brain, and C) nh-UCBSC treated brain 7 days following stroke. 
Gates were established based on isotype stained brain samples.  D) Quantification of 
macrophage cell numbers in each treatment group showed a significant increase in macrophages 
in the stroke brain 7 days following stroke, and a decrease in the UCBSC treated stroke group, 
though there is no significant difference between the stroke and UCBSC treated groups (p<0.05). 
Average values (±SEM) from pooled data (n=5) are presented. 
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Figure 7. Population of Microglia increases in the ischemic brain 7 days following stroke, and is 
reduced in UCBSC treated stroke brains. Flow cytometry showing microglia populations in A) 
healthy control brain, B) stroke brain, and C) nh-UCBSC treated brain 7 days following stroke 
(n=5). Quantification of the absolute numbers of microglia in each treatment group shows an 
increase in microglia in stroke brains 7 days following stroke, and a decrease in the nh-UCBSC 
treated group, but these changes were not statistically significant (p<0.05). Average values 
(±SEM) from pooled data are presented.  
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Figure 8. UCBSC treatment normalizes the expression of T cell related RNA transcripts at 7 days 
following stroke. A) RNA expression of LCP2 is significantly increased 7 days following stroke 
and normalized in the animals treated with UCBSC. B) RNA expression of CD4 is significantly 
increased 7 days following stroke and is normalized in the animals treated with UCBSC. C) RNA 
expression of GM2A is significantly increased 7 days following stroke and is normalized in the 
animals treated with UCBSC. D) RNA expression of SH2B3 is significantly increased 7 days 
following stroke and is normalized in the animals treated with UCBSC.  
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Figure 9. Administration of nh-UCBSC normalizes the number of CD3+ T cells present in the 
brain 7 days following MCAO. Flow cytometry shows the CD3+ T cell population in the brain of A) 
healthy control rats, B) stroke animals, and C) nh-UCBSC treated stroke animals. (n=5) Gating 
was established based on isotype stained brain samples. D) Quantification of the absolute 
number of CD3+ T cells in control, stroke, and UCBSC treated stroke brains shows a significant 
increase in the total number of CD3+ T cells in the brain 7 days following MCAO (p<0.05), and a 
normalization of the T cell population in the UCBSC treated animals. Average values (±SEM) 
from pooled data are presented.  
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Figure 10. nh-UCBSC treatment normalizes the number of CD4+ Helper T cells 7 days following 
stroke. Population of CD4 (defined as CD3+CD8a-CD4+) and CD8a (defined as CD3+CD4-
CD8a+) T cells in A) healthy control brain B) MCAO brain and C) nh-UCBSC treated MCAO brain 
7 days following stroke. (n=5) Quad gates were established based on isotype stained brain 
samples. D) Quantification of CD4+ T cell populations show a significant increase in cell number 
in the MCAO group (p<0.05), and a normalization of the population with nh-UCBSC treatment. E) 
Quantification of CD8a+ cytotoxic T cells showed no significant difference in cell number between 
treatment groups. All gates were determined using isotype stained control tissue. Average values 
(±SEM) from pooled data are presented.  
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Figure 11. Population of activated CD3+CD8a-CD4+ CD25+ Helper T cells are significantly 
increased in the brain 7 days following stroke, and normalized in nh-UCBSC treated stroke 
brains. Flow cytometry of CD4+CD25+ cell populations in A) Healthy control brain B) Ischemic 
brain, and D) nh-UCBSC treated stroke brains 7 days following MCAO. (n=5) Quad gates were 
established based on isotype stained brain samples. C) Quantification of CD4+CD25+ cell 
populations. Cell number is significantly increased in stroke brains 7 days following stroke 
(p<0.05) and is normalized with nh-UCBSC treatment. All gates were defined using isotype 
stained control tissue. Average values (±SEM) from pooled data are presented.  
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Figure 13. Populations of CD3+CD4-CD8a+CD25+ activated Cytotoxic T cells do not change 
significantly 7 days following ischemia. Flow cytometry of CD8a+CD25+ cell populations in A) 
Healthy control brains, B) stroke brains, and D) nh-UCBSC treated brains 7 days following stroke. 
(n=5) Quad gates were established based on identically stained brain samples with isotype 
specific control antibodies. C) Quantification of CD8a+CD25+ cell population in the brain 7 days 
following stroke. Populations showed no significant difference between treatment groups 
(p<0.05). All gates were determined using isotype stained control tissue. Average values (±SEM) 
from pooled data are presented.  
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Figure 14. nh-UCBSC treatment normalizes CD3+CD4+FoxP3+ expression 7 days following 
stroke. Flow cytometry of A) healthy control brain, B) stroke brain, and C) nh-UCBSC treated 
brain 7 days following MCAO surgery. (n=5) Quad gates were established based on isotype 
stained brain samples. D) Quantification of FoxP3+ expression in all treatment groups shows an 
increase in expression in the ischemic brain, though that change is not statistically significant 
(p<0.05). Average values (±SEM) from pooled data are presented. 
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Figure 15. Total number of mature B cells (defined as CD3-CD161-CD45RA+) present in the 
brain decreases 7 days following stroke and normalizes with nh-UCBSC treatment. Flow 
cytometry of mature B cells in A) healthy control brain, B) stroke brain, and C) nh-UCBSC treated 
stroke brain 7 days following MCAO surgery. (n=5) Gating was established based on isotype 
stained brain samples. D) Quantification of total cell number of mature B cells in the brain in all 
treatment groups shows a decrease in cell number in the ischemic brain and a normalization with 
nh-UCBSC treatment, though these changes are not statistically significant (p<0.05). Average 
values of pooled data (±SEM) are presented.  
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